Hey. When you guess like that makes it sound like you are being treated like a mushroom. Prolly the best we can do when the company doesn't tell us much.
So, you don't think that the PDD data will be included with the AD data in the peer-reviewed journal? Since the two are closely related, it would seem a good opportunity to provide a comprehensive analysis of blarcamesine's efficacy & safety with the implication that it'll be effective therapy in addressing multiple degenerative CNS indications.